Universal reference book for medicines
Product name: ZODAK В® (ZODAC В® )

Active substance: cetirizine

Type: The blocker of histamine H 1 -receptors.
Anti-allergic drug
Manufacturer: ZENTIVA (Czech Republic)
Composition, form of production and packaging
Tablets covered with a film coat of white or almost white color, oblong, with a risk for division on one side.
1 tab.

cetirizine dihydrochloride 10 mg

Excipients: lactose monohydrate - 73.4 mg, corn starch - 33 mg, povidone 30 - 2.4 mg, magnesium stearate - 1.2 mg.

The composition of the membrane: hypromellose 2910/5 - 3.45 mg, macrogol 6000 - 0.35 mg, talc - 0.35 mg, titanium dioxide - 0.80 mg, simethicone emulsion SE4 - 0.05 mg.

7 pcs.
- blisters (1) - packs of cardboard.
10 pieces.
- blisters (1) - packs of cardboard.
10 pieces.
- blisters (3) - packs of cardboard.
10 pieces.
- blisters (6) - packs of cardboard.
10 pieces.
- blisters (9) - packs of cardboard.
10 pieces.
- blisters (10) - packs of cardboard.
Drops for oral administration are clear, from colorless to light yellow in color.
1 ml (20 drops)

cetirizine dihydrochloride 10 mg

Excipients: methylparahydroxybenzoate, propyl parahydroxybenzoate, glycerol, propylene glycol, sodium saccharinate dihydrate, sodium acetate trihydrate, acetic acid glacial, purified water.

20 ml - bottles of dark glass (1) with a lid-dropper - packs of cardboard.


Description of the drug approved by the manufacturer for the printed edition of 2016.


The blocker of histamine H 1 -receptors.
Cetirizine is a competitive antagonist of histamine, with almost no anticholinergic and antiserotonin action. Has a pronounced anti-allergic effect, prevents development and facilitates the course of allergic reactions. Has antipruritic and anti-exsudative effect. Affects the early stage of allergic reactions, and also reduces the migration of inflammatory cells; oppresses the selection of mediators involved in a late allergic reaction. Reduces the permeability of capillaries, prevents the development of edema of tissues, relieves spasm of smooth muscles. Eliminates the skin reaction to the administration of histamine, specific allergens, and also to cooling (with cold urticaria). In therapeutic doses, it practically does not have a sedative effect. Against the background of the course, tolerance does not develop.
The effect of the drug begins in 20 minutes (in 50% of patients), after 1 hour (95%
patients) and is maintained for 24 hours.


After ingestion, cetirizine is rapidly and well absorbed from the digestive tract.
C max is determined after about 30-60 minutes. Eating does not have a significant effect on the amount of absorption, but in this case, the rate of absorption is slightly reduced.

Binding to plasma proteins is approximately 93%.
The value of V d is low (0.5 l / kg), the preparation does not penetrate into the cell. The drug does not penetrate the BBB. Excreted in breast milk.

Cetirizine is poorly metabolized in the liver with the formation of an inactive metabolite.
When applied at a dose of 10 mg for 10 days, there is no accumulation of the drug.

After a single dose of a single dose, T 1/2 is about 10 hours. 70% of the dose is excreted by the kidneys mainly unchanged.
The system clearance is about 54 ml / min.
Pharmacokinetics in special clinical cases

In children aged 2 to 12 years, T 1/2 decreases to 5-6 hours.

Against the backdrop of chronic diseases and in elderly patients there is an increase in T 1/2 by 50% and a decrease in clearance by 40%.

In case of renal dysfunction (CC below 11-31 ml / min) and in hemodialysis patients (QC less than 7 ml / min), T 1/2 increases 3 times, the clearance decreases by 70%.

Hemodialysis is ineffective.


- seasonal and year-round allergic rhinitis and conjunctivitis;

- itching allergic dermatoses;

- Pollinosis (hay fever);

- urticaria (including chronic idiopathic);

- Quincke's edema.


Before using Zodak В® it is necessary to consult a doctor to avoid complications.

The drug is taken orally, regardless of food intake.


Adults and children over the age of 12 years are prescribed, usually in a dose of 10 mg (1 tab.) 1 time / day.

For children aged 6 to 12 years, Zodak В® is prescribed, as a rule, 10 mg (1 tab.) 1 time / day or 5 mg (1/2 tab.) 2 times / day, morning and evening.

In patients with renal insufficiency, the dose of the drug should be reduced depending on the CK: for KK 30-49 ml / min - 5 mg 1 time / day;
at 10-29 ml / min - 5 mg every other day.
When appointing the drug to elderly patients with renal insufficiency, the dose should be adjusted depending on the magnitude of the SC.

CK for men can be calculated based on the serum creatinine concentration, according to the following formula:

CK (ml / min) = [140 - age (years)]? Body weight (kg) / 72? KK serum.
(mg / dL)
KK for women can be calculated by multiplying the obtained value by a factor of 0.85.

Renal insufficiency KK (ml / min) Dosing regimen

Norm> 80 10 mg / day

Light 50-79 10 mg / day

Average 30-49 5 mg / day

Heavy 10-29 5 mg every other day

Terminal stage - patients on hemodialysis <10 The drug is contraindicated

Patients with a dysfunction only liver function correction dosage is not required.

If you miss the time of taking the drug accidentally , the next dose should be taken as soon as possible.
In the event that the time of the next administration of the drug is approaching, the next dose should be taken on schedule, without increasing the total dose.
Zodak В® can be taken regardless of the time of ingestion.

Tablets, coated with a shell, should be swallowed whole, washed down with a small amount of water.


Before taking the drop, dissolve in water.

Adults and children over the age of 12: 10 mg of cetirizine (20 drops) 1 time / day, daily, preferably in the evening.

Children aged 6 to 12 years: 10 mg cetirizine (20 drops) 1 time / day or 5 mg cetirizine (10 drops) 2 times / day, morning and evening.

Children aged 2 to 6 years: 5 mg cetirizine (10 drops) 1 time / day or 2.5 mg cetirizine (5 drops) 2 times / day, morning and evening.

Children aged 1 to 2 years: 2.5 mg (5 drops) 2 times / day.

In patients with renal insufficiency , the recommended dose should be reduced by a factor of 2.

In patients with impaired liver function, the dose of cetirizine should be somewhat reduced to 5 mg (10 drops) per day.

In elderly patients, patients with normal renal function are not required to adjust the dose.

Instructions for opening a vial with a safety lid

The bottle is closed with a lid with a safety device that prevents its opening by children.
The bottle opens when the lid is pressed hard down and then unscrewed against the clockwise direction. After use, the lid of the vial must be tightened again firmly.

The drug is usually well tolerated.
Adverse reactions occur rarely and have a transient nature. Determination of the frequency of adverse reactions: very often (? 1/10), often (? 1/100, <1/10), infrequently (? 1/1000, <1/100), rarely (? 1/10 000, <1 / 1000), very rarely (<1/10 000), the frequency is unknown (according to available data, it is not possible to determine the occurrence frequency of the side effect).
From the hemopoietic system: very rarely - thrombocytopenia.

From the immune system: rarely - hypersensitivity reactions;
very rarely - anaphylactic shock.
From the nervous system: often - headache, drowsiness, fatigue, dizziness;
infrequently paresthesia; rarely - convulsions, impaired motor function; very rarely - perversion of taste, dyskinesia, dystonia, fainting, tremor, tick; frequency unknown - memory impairment, incl. amnesia.
Disorders of the psyche: infrequent excitation;
rarely - aggression, confusion, depression, hallucinations, sleep disturbance; frequency is unknown - suicidal ideation.
From the side of the organ of vision: very rarely - disorders of accommodation, blurred vision, nystagmus.

From the side of the organ of hearing and balance: the frequency is unknown - vertigo.

On the part of the digestive system: often - dry mouth, nausea;
infrequently - diarrhea, abdominal pain.
From the cardiovascular system: rarely - tachycardia.

From the respiratory system: often - rhinitis, pharyngitis.

From the side of metabolism: rarely - an increase in body weight.

From the urinary system: very rarely - dysuria, enuresis;
frequency unknown - urinary retention.
From the laboratory: rarely - a change in functional liver samples (increased activity of hepatic transaminases, alkaline phosphatase, GGT and bilirubin concentrations);
very rarely - thrombocytopenia.
From the skin and subcutaneous tissues: infrequently - rash, itching;
very rarely - persistent erythema.
Allergic reactions: rarely - hives;
very rarely - angioedema.
Common reactions: infrequent - asthenia, malaise;
rarely - peripheral edema; frequency unknown - increased appetite.

- terminal stage of renal failure (CC <10 ml / min) (for taking tablets);

- hereditary intolerance to galactose, insufficiency of lactase or glucose-galactose malabsorption syndrome (for taking tablets);

- Children's age to 6 years (for taking tablets);

- Children under 1 year of age (for taking drops);

- Pregnancy;

- the period of lactation (breastfeeding);

- Hypersensitivity to the components of the drug.

With caution: chronic renal failure of moderate severity (correction of dosing regimen is required), elderly age (glomerular filtration may be reduced).
When taking the pill: chronic liver disease (hepatocellular, cholestatic or biliary cirrhosis) (dose correction is required only with the concomitant decrease in glomerular filtration rate).

Contraindicated in pregnancy and lactation (breastfeeding).


For patients with severe renal dysfunction, the drug is prescribed by the doctor individually, in a reduced dose.


For patients with severe impairment of liver function, the drug is prescribed by the doctor individually, in a reduced dose.


Tablets are used in children older than 6 years.


To the elderly, the drug is prescribed by the doctor individually, in a reduced dose.


Patients with impaired renal function, liver and elderly patients should consult a doctor before taking the drug.

It is not recommended simultaneous use of drugs, oppressive central nervous system, alcohol.

Indication for patients with diabetes mellitus

Drops do not contain sugar, so they can be prescribed to patients with diabetes mellitus.

Impact on the ability to drive vehicles and manage mechanisms

During the period of treatment, patients should refrain from engaging in potentially dangerous activities that require a high concentration of attention and speed of psychomotor reactions.


Symptoms: confusion, dizziness, drowsiness, blocking, stupor, weakness, anxiety, irritability, sedation, fatigue, headache, mydriasis, itching, tachycardia, tremor, urinary retention, dry mouth, diarrhea, constipation (most often when taking 50 mg cetirizine per day), malaise.

Treatment: gastric lavage, the appointment of activated charcoal, the conduct of symptomatic therapy.
The specific antidote is not known. Hemodialysis is ineffective.

Clinically significant interaction of cetirizine with other drugs has not been established.

Joint reception with theophylline (400 mg / day) leads to a decrease in the total clearance of cetirizine (the kinetics of theophylline does not change).

In recommended doses does not enhance the effect of ethanol (with a blood concentration of not more than 0.8 g / l), however, it is recommended to refrain from taking ethanol during treatment with the drug.


The drug is approved for use as a means of OTC.



Tablets should be stored at a temperature of no higher than 25 В° C.
Shelf life - 3 years.
Drops do not require special storage conditions.
Shelf life - 3 years.
The drug should be stored out of the reach of children.

Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y

Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!